A federal outside panel voted Thursday to ease rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is not binding. The FDA has given no clear statement on whether it will move in step with the panel. The move came after weeks of community hearings. Wellness backers pushed hard for wider access. RFK Jr. was among them. Critics say these compounds have little hard evidence of safety or help for most uses. The call could alter how the agency handles a part of the wellness market that is growing very fast. Market observers are watching to see if the regulator moves in step. A spokesperson for the regulator offered no deadline for a follow-up. Industry voices argue the change would widen access to substances users swear by. Skeptics warn that looser rules could weaken safeguards across a barely regulated market. The advisory vote only opens the door to a change, and the last word rests with the federal agency.